

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)

4) 1999/115 B DE

A61L15144

19



Europäisches Patentamt
European Patent Office
Office européen des brevets

11 Publication number:

0 196 769
A2

12

EUROPEAN PATENT APPLICATION

21 Application number: 86301330.6

51 Int. Cl. 4: A61L 15/03

22 Date of filing: 24.02.86

30 Priority: 25.02.85 US 705194
30.08.85 US 770968

43 Date of publication of application:
08.10.86 Bulletin 86/41

84 Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

71 Applicant: Rutgers, The State University of New
Jersey

New Brunswick New Jersey 08900(US)

72 Inventor: Chien, Yie Wen
5, West Lake Court
North Brunswick, NJ 08902(US)
Inventor: Lee, Chia-Shun
17, Forest Glen
Highland Park, NJ 08904(US)

74 Representative: Watkins, Arnold Jack et al
European Patent Attorney Frank B. Dehn & Co.
Imperial House 15-19 Kingsway
London WC2B 6UZ(GB)

54 A novel transdermal pharmaceutical absorption dosage unit.

57 A novel transdermal pharmaceutical polymer matrix dosage unit is provided which comprises a backing layer, an adjoining layer of a solid polymer matrix in which the pharmaceutical is microdispersed and a final biologically acceptable adhesive polymer layer which has dispersed therein a skin permeation enhancer.

EP 235 258

W 08711291

454818540

5045319

4806341

5286130

EP 0 196 769 A2

A NOVEL TRANSDERMAL PHARMACEUTICAL ABSORPTION DOSAGE UNIT

This invention relates to a novel transdermal pharmaceutical absorption dosage unit comprising a backing layer, an intermediate adjoining layer of solid polymer matrix in which the pharmaceutical is dispersed, and a final biologically acceptable adhesive layer which is in communication with the solid polymer matrix layer and is adapted to adhere to the skin of a subject being administered the pharmaceutical, the adhesive layer having dispersed therein an effective amount of one or more skin permeation enhancing compounds for the pharmaceutical dispersed in the polymer matrix layer.

It has been found in the prior art that certain pharmaceuticals are absorbed to a degree through the skin. This is referred to as transdermal pharmaceutical absorption. One means of effecting transdermal absorption has been to distribute the pharmaceutical within a polymeric disc or a container of a gel, which is brought into contact with an area of the skin of the subject to be treated with the pharmaceutical. Also, ointments or lotions containing a desired pharmaceutical have been applied to an area of the skin of the subject to be treated. Problems encountered in such treatment include inadequate control over the rate and duration of the transdermal absorption or the rate can be too slow in the case of certain dosage forms, especially from pharmaceutical-containing discs or pharmaceutical-containing gel container dosage units or pads. It has been found that the transdermal absorption rates of certain pharmaceuticals can be increased by use of absorption-promoting compounds (also referred to as skin permeation enhancers) with the pharmaceutical to be absorbed when compounding the polymeric disc or the pharmaceutical-containing gel.

It is desired to improve the dosage unit forms or devices by which pharmaceuticals are transdermally absorbed, especially in view of the importance of administration of pharmaceuticals by this means. The desired transdermal absorption of pharmaceuticals would provide an avoidance of gastrointestinal incompatibility with the pharmaceuticals and unwanted destruction of the pharmaceutical by metabolism in the gastrointestinal tract and by a "first pass" hepatic metabolism. The transdermal absorption minimizes inter-and intra-patient variations regarding such incompatibilities and metabolisms. By transdermal absorption it is deemed possible to provide more constant pharmaceutical concentration in the body and to realise a greater pharmaceutical efficiency. It is possible, by proper transdermal absorption, to reduce the frequency of effective dosing. Transdermal administration provides most of the advantages of intravenous dosing without the necessity of hospitalization and the accompanying discomfort and inconvenience.

It is desired that improved transdermal pharmaceutical absorption dosage unit forms and processes of transdermal administration be developed. A number of advantages would result.

This invention provides a transdermal pharmaceutical containing matrix dosage unit comprising:

a) a backing layer which is substantially impervious to the pharmaceutical to be delivered transdermally;

b) a polymer matrix disc layer which is adhered to said backing layer and which has micro-dispersed therein an amount of the pharmaceutical which will provide a dosage amount of the pharmaceutical to be delivered transdermally; and

c) an adhesive layer which is adhered to said pharmaceutical-containing polymer matrix disc layer and which has distributed therein an effective amount of one or more skin absorption enhancers which provide substantial skin absorption enhancement for said pharmaceutical;

said dosage unit having an Enhancing Factor (as hereinafter defined) of at least 1.2.

The backing layer is made from materials that are substantially impermeable with regard to the pharmaceutical of the transdermal dosage unit. It can be made of polymers such as polyethylene, polypropylene, polyvinylchloride, polyesters such as poly(ethylene phthalate), and laminates of polymer films with metallic foils such as aluminium foil.

The polymer matrix disc layer is fabricated from biologically acceptable polymers. The polymer matrix disc layer which has the pharmaceutical distributed therein can suitably be made of a medical-grade silicone polymer such as polydimethylsiloxane polymer. The pharmaceutical is suitably dispersed in the silicone polymer, to which mixture a curing agent is suitably added. The polymer-pharmaceutical mixture is then formed into a layer of an appropriate thickness and is cured. The matrix layer is adhered to the backing layer which can be done directly. Other suitable polymers which can be used in the formulation of the polymer matrix disc layer are elastomers or thermoplastics. Care must be taken that the polymer selected is compatible with the pharmaceutical, permits its release for transdermal absorption and is free or sufficiently free from any biologically unacceptable components. The polymer matrix disc layer preferably provides microdispersion compartments having a cross sectional dimension of from about 10 to about 200 microns.


Finally, the adhesive layer is applied to the polymer matrix disc layer. The skin absorption enhancer compound - (elsewhere referred to as a skin permeation enhancer) is mixed thoroughly with the adhesive polymer which is suitable for adhesion to the skin locus to which the transdermal matrix delivery dosage unit will be applied. The adhesive polymer-skin permeation enhancer layer can be applied to the polymer matrix disc layer by spraying or by solvent casting. Such a layer is desirably thin, having a thickness in the micron range, preferably having a thickness in the range of from 10 to 200 microns, more preferably from 20 to 180 microns and still more preferably from 30-150 microns.

The transdermal pharmaceutical absorption dosage units of this invention have an Enhancing Factor of at least 1.2, preferably at least 1.3, and more preferably at least about 2.0. Enhancing Factor is defined as the ratio of normalized permeation rate [in mcg/cm²/hr] of a dosage unit of this invention with skin permeation enhancer to the normalized permeation rate of a corresponding dosage unit without enhancer.

The invention thus provides the means for a method of administering a pharmaceutical transdermally by forming a pharmaceutical-containing polymer matrix disc dosage unit having a polymer matrix disc layer which has the pharmaceutical dosage dispersed therein, to which matrix disc is adhered a skin permeation enhancer-containing adhesive layer and, by applying said dosage unit by way of said adhesive layer to the skin of the subject to be treated, whereby said pharmaceutical is transdermally administered systematically to said subject to achieve systemic effects.

The backing layer can be made of any suitable material which is impermeable to the pharmaceutical of the polymer matrix layer. The backing layer serves as a protective cover for the matrix layer and provides also a support function. Examples of materials that are suitable are films of high and low density polyethylene, polypropylene, polyvinylchloride, polyesters such as poly(ethylene phthalate) and the like. Preferably, the materials for the backing layer are laminates of such polymer films with a metal foil such as aluminum foil. In such laminates, a polymer film of the laminate will usually be in contact with the polymer matrix layer. The backing layer can overlay the matrix and adhere

sive layer as desired for protection and to provide the desired pharmaceutical elegance of the final matrix dosage unit form. The protective layer can be any appropriate thickness which will provide the desired protective and support functions. A suitable thickness will be from about 10 to about 200 microns. Desirably, the thickness will be from about 20 to about 150 microns, and preferably be from about 30 to about 100 microns. The polymer matrix layer can be made from silicone elastomers of the general polydimethylsiloxane structure, such as silicone polymers of the following formula:



wherein R is alkyl or alkoxy containing 1-7 carbon atoms, vinyl or phenyl and wherein n is about 100-5000.


The silicone polymers selected preferably are cross-linkable at moderate temperatures such as at room temperature, using cross-linking catalysts which are biologically acceptable in the final polymer matrix and which are compatible with the pharmaceutical to be used in making the polymer matrix dosage forms. Some suitable siloxane polymers are cross-linkable copolymers having dimethyl and methylvinyl siloxane units, which can be cross-linked as by using a suitable peroxide catalyst. Other cross-linking sites can be present in the polysiloxane elastomers used. Suitable siloxane medical-grade polymers are sold under the designations Silastic 382, Q7-4635, Q7-4650, Q7-4665, Q7-4735, Q7-4750, Q7-4765 and MDX-4-4210.

Generally, polymers used to form the biologically acceptable polymer matrix are those capable of forming thin walls or coatings through which pharmaceuticals can pass at a controlled rate. Suitable polymers are biologically and pharmaceutically compatible, non-allergenic and insoluble in and non-irritating to body fluids or tissues with which the device is contacted. The use of soluble polymers is to be avoided since dissolution or erosion of the matrix would affect the release rate of the pharmaceutical as well as the capability of the dosage unit to remain in place for convenience of removal.

Exemplary materials for fabricating the biologically acceptable polymer matrix include polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylene/vinyl acetate

copolymers, silicone elastomers, especially the medical-grade polydimethylsiloxanes, neoprene rubber, chlorinated polyethylene, polyvinyl chloride; vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), butyl rubber, epichlorohydrin rubbers, ethylene-vinyl alcohol copolymer, ethylene-vinylalcohol copolymer; silicone copolymers, for example, silicone-polycarbonate copolymers; cellulose polymers, for example methyl or ethyl cellulose hydroxypropyl methyl cellulose, and cellulose esters; polycarbonates; polytetrafluoroethylene; and the like. For best results, the biologically acceptable polymer matrix should be selected from polymers with glass transition temperatures below room temperature. The polymer may, but need not necessarily, have a degree of crystallinity at room temperature. Cross-linking monomeric units or sites can be incorporated into such polymers. For example, cross-linking monomers can be incorporated into polyacrylate polymers, which provide sites for cross-linking the matrix after microdispersing the pharmaceutical into the polymer. Known cross-linking monomers for polyacrylate polymers include polymethacrylic esters of polyols such as butylene diacrylate and dimethacrylate, trimethylol propane trimethacrylate and the like other monomers which provide such sites include allyl acrylate, allyl methacrylate, diallyl maleate and the like.

The adhesive layer is suitably made using a silicone adhesive, such as a polydimethylsiloxane adhesive of the following formula:



wherein x shows the unit is repeated to the extent to provide desired properties.

For example, adhesive products sold by Dow Corning under the designation DC-355 are suitable for use in making the adhesive layer. The adhesive polymer must be biologically acceptable and compatible with the pharmaceutical and skin permeation enhancer used. Certain polyacrylate adhesive polymers (in the form of an alkyl ester, amide, free acid, or the like) can also be used with some pharmaceuticals. Other suitable hypoallergenic pressure-sensitive contact adhesive compositions are also known. A preferred adhesive layer is pressure-sensitive.

The adhesive layer then is finally covered with a releasable protective layer liner which is made from materials which are substantially impermeable to the pharmaceutical, the skin permeation enhancer used and any other components of the polymer matrix dosage unit. The polymer materials and metal foil laminates used for the backing layer can be used to make the protective layer, provided the layer is made strippable or releasable such as by applying conventional siliconizing.

In making the pharmaceutical-containing polymer matrix disc layer, silicone elastomers such as polydimethylsiloxane of the formula described above can suitably be used. In making nitroglycerin-dispersed polymer matrix disc dosage units, it has been found suitable to use lactose as a dispersing agent. Other suitable dispersing agents can be used instead of lactose. In the case of normally liquid pharmaceutical, a solid-type dispersing agent is suitably used. For pharmaceuticals which are solids, for example those which are solid between about 25°C and 60°C, water-soluble, high molecular weight polyols, are generally suitable. For example, polyethylene glycols such as those having greater than a molecular weight of 400 can be used. Other suitable dispersing agents known to the formulating art can be used. In the case of some solid pharmaceuticals, it is quite acceptable not to use a dispersing agent. Depending upon the drug loading desired, a suitable amount of a dispersing agent has been found to be 1-9 equivalents - (by weight) based on the weight of nitroglycerin. The pharmaceutical then is added to the polymer used to make the matrix disc layer. The amount of the pharmaceutical added depends upon the amount of pharmaceutical dosage desired in each dosage unit and the amount which can be incorporated into the polymer matrix disc to retain suitable structural, diffusion and other properties in the final matrix disc. It has been found, for example, that pharmaceutical can be satisfactorily added to 70 parts of the polymer used in making the matrix disc, such as silicone elastomers. The mixture of the polymer and pharmaceutical is then thoroughly mixed using a high-torque mixer to form a homogeneous microdispersion of the pharmaceutical in the polymer. With continued agitation, an amount of cross-linking catalyst is desirably added together with relatively low molecular weight polymer having a compatible chemical struc-

ture. For example, when polydimethylsiloxane is used as the polymer, a relatively low molecular weight polydimethylsiloxane and a cross-linking catalyst is added (such as 10 parts by weight of the low molecular weight polydimethylsiloxane and 30 drops of stannous octanoate per 100g. amount of the final polydimethylsiloxane-pharmaceutical mixture) to the above illustrative composition of 20 parts of pharmaceutical dispersion and 70 parts of polydimethylsiloxane polymer. Again, the mixture is agitated with a high-torque mixer to form a uniform admixture. After each mixing step, the composition is subjected to vacuum to remove any entrapped air.

The deaerated mixture is then placed in a device maker and heated to suitable elevated temperature to promote cross-linking. A suitable temperature for cross-linking when the polymer used is polydimethylsiloxane of the above formula and the cross-linking catalyst is stannous octanoate, is from about 10°C to about 200°C, desirably about 20°C to about 100°C. The temperature used should not cause significant degradation of the pharmaceutical. The polymer matrix sheet desirably is about 0.05 to 5 mm, preferably about 0.1 to about 3 mm in thickness. The resulting cross-linked polymer matrix sheet is removed from the device maker and can be cut to form discs with desired shapes and sizes. The discs are then attached to a backing sheet, as described above, using an adhesive. The discs generally should not exceed about 100 sq. cm. in area, suitably about 5 to 100 sq. cm., preferably, about 8 to about 80 sq. cm., generally about 10 to 60 sq. cm. being more preferable. The shape of the discs can vary; they can be circular, square, rectangular or other desired shape.

The pharmaceutical-containing polymer matrix disc layer, generally speaking, should contain some amount of excess of the dispersed pharmaceutical over the dosage amount desired to be transdermally absorbed by the subject to be treated. Ordinarily, this excess is small, such as less than 2-fold excess. Generally speaking, an amount of the pharmaceutical used, which is sufficient, is less than 2 to about 10 times the desired dosage to about less than 2 to about 5 times the desired dosage to be transdermally absorbed being adequate, depending upon the physiochemical properties of the pharmaceutical, as well as the nature of the polymer of the matrix disc layer and other factors.

The adhesive polymer layer containing the skin permeation enhancer is made as by dissolving the enhancer compound in a solvent for the enhancer which is compatible with the adhesive polymer solution used to make the adhesive layer containing the skin permeation enhancer. Any suitable amount of solvent can be used as necessary to dissolve the quantity of enhancer to be admixed with the adhesive polymer solution used. For example, 3 to 10 parts of solvent can be used to dissolve one part of skin permeation enhancer, depending upon the solubility of the enhancer. When using polydimethylsiloxane adhesive solution, it has been found suitable to use 2 to 20 parts of skin

permeation enhancer in 20 to 50 parts of solvent (such as acetone, methyl ethyl ketone, thyl acetate or other suitable solvent) and add the solution to 100 parts of the adhesive solution. The enhancer-adhesive combination is thoroughly mixed and a coating thereof is applied using a film coating machine to the matrix disk layer or to a strippable release liner, as described above. Preferably, in order to assure adequate adhesion of the adhesive polymer layer to the skin of the subject treated, an enhancer-adhesive polymer solution having a relatively low concentration of enhancer, e.g., 1-2 percent based on the weight of the adhesive polymer is used to apply a coating to the release liner. The thickness of this coating ordinarily is a minor percentage of the thickness of the final adhesive layer, such as 20-40 percent of the total adhesive polymer layer. The remainder of the adhesive polymer layer having a suitable higher concentration of the enhancer is used to coat the matrix disc layer. Suitable higher concentrations of enhancer are usually 10 to about 30 percent based on the adhesive polymer weight, depending upon solubility, desired final amount of skin enhancer agent and other factors. The solvent of the respective coatings is removed by evaporation. The respective coatings are combined to make the final adhesive polymer-enhancer agent layer by application of constant pressure.

A suitable release liner being a poly(ethylene phthalate) laminated with aluminum foil. The poly(ethylene phthalate) side to which the adhesive-enhancer coating is applied, is made strippable by conventional siliconizing or by other suitable means. The thickness of the adhesive-enhancer layer normally is suitably about 10 to about 200 microns, preferably about 30 to about 150 microns. The amount of enhancer in the adhesive layer depends in part on the rapidity at which it is desired that the pharmaceutical be absorbed. Generally speaking, about 1 to about 30 percent of skin permeation enhancer based on the weight of the adhesive is suitable depending upon the enhancer, matrix polymer, adhesive and other factors. Desirably, about 2 to about 20 percent of skin permeation enhancers are used depending upon the above recited factors. The adhesive layer containing the skin permeation enhancer is applied to the polymer matrix disc surfaces by application of a constant pressure.

The four-layer transdermal pharmaceutical polymer matrix dosage units are excised. The backing layer as desired can be shaped around the sides of the dosage unit including the polymer matrix layer if such protection is desired. The resulting pharmaceutical polymer matrix dosage unit forms are then placed in appropriate storage until they are to be applied in transdermal treatment.

At least one pharmaceutical is dispersed in the polymer matrix disc layer. The type of pharmaceutical which may be dispersed in the polymer matrix disc layer includes any pharmaceutical which is capable of being transdermally or topically administered to a subject to be treated. The pharmaceutical used should have a daily effective dose of less than about 100 mg. With the controlled release of the pharmaceutical at a relatively steady rate over a prolonged period, typically 24 hours or longer, the patient is provided with the benefit of a steady infusion of the pharmaceutical over a prolonged period. As examples of pharmaceuticals which can be included in the polymer matrix disc layer of the present invention, there may be mentioned the following: alpha-[1(methylamino)ethyl]-benzene methanol, which is useful as an adrenergic (bronchodilator); N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide, useful as a narcotic analgesic; furosemide and 6-chloro-3, 4-dihydro-2H-1, 2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, useful as diuret-

ics; and 2-diphenylmethoxy-N, N-dimethylethanamine, useful as an antihistamine. Other useful drugs include: antimicrobial agents such as penicillins, cephalosporins, tetracycline, oxytetracycline, chlortetracycline, chloramphenicol; and sulfonamides, sedatives and hypnotics such as pentobarbital, sodium pentobarbital, secobarbital sodium, codeine (abromoisovaleryl) urea, and carbromal; psychic energizers such as 3-(2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate; tranquilizers such as diazepam, chlordiazepoxide hydrochloride, reserpine, chlorpromazine hydrochloride, and thiopropazate hydrochloride; hormones such as adrenocorticosteroids, for example, 6-methyl-prednisolone; androgenic steroids, for example, testosterone, methyltestosterone, and fluoxymesterone; estrogenic steroids, for example, estrone, estradiol and ethinyl estradiol; progestational steroids, for example, 17a-hydroxyprogesterone and acetate, medroxyprogesterone and acetate, 19-norprogesterone, and norethindrone; thyroxine; antipyretics such as aspirin, salicylamide, methylsalicylate triethanolamine and salicylate; morphine and other narcotic analgesics; hypoglycemic agents, for example, sulfonyl ureas such as glypizide, glyburide and chlorpropamide and insulin; antispasmodics such as atropine, methscopolamine bromide, methscopolamine bromide with phenobarbital; antimalarials such as the 4-aminoquinolines, 9-aminoquinolines, and pyrimethamine; adrenergic block agent such as metoprolol; antiarthritic agents such as sulindac; nonsteroidal anti-inflammatory agents such as ibuprofen and naproxen; vasodilators such as dipyridamole, isosorbide dinitrate; antihypertension agents such as propranolol, methyl dopa and prazosin; contraceptive agents such as levonorgestrel/estradiol combination and ethynodiol diacetate/estrogen combination; agents for treating duodenal ulcers such as cimetidine; and nutritional agents such as vitamins, essential amino acids, and essential fats. The above listing of pharmaceuticals is merely exemplary of the transdermally applicable pharmaceuticals. It is contemplated that any pharmaceutical can be utilized may be transdermally administered by use of this invention.


It will be appreciated that the pharmaceutical may be added to the above mixture not only in the form of the pure chemical compound, but also in admixture with other pharmaceuticals which may be transdermally applied or with other ingredients which are not incompatible with the desired objective of transdermally administering the pharmaceutical to a patient. Thus, simple pharmacologically acceptable derivatives of the pharmaceuticals such as ethers, esters, amides, acetals, salts and the like may be used. In some cases, such derivatives may actually be preferred.

The skin permeation enhancers which can be used in carrying out this invention can vary. Ones that give preferred results with the polymer matrix dosage unit form having a specific pharmaceutical can vary. In some instances the use of permeation enhancer in making a polymer matrix dosage form will result in good or even excellent absorption for one pharmaceutical but may result in no or relatively low enhancement when another pharmaceutical is used. Use of combinations of two or more skin permeation enhancer compounds frequently results in superior results, such as greater transdermal absorption.

Specific skin permeation enhancers which can be used in making the polymer matrix dosage forms of this invention include saturated and unsaturated fatty acids and their esters (e.g. alkyl esters), alcohols, monoglycerides, glycerylglycine, diethanolamides, triethanolamine complexes and N, N-dimethylamides, derivatives and acetate esters, examples being oleic acid, propyl oleate, monoolein, oleyl acetate, propyl myristate, mono-myristein, myristyl alcohol, oleyl al-

cohol, myristyl N, N-dimethyl amide, stearic acid and stearyl alcohol, propyl stearate, monostearin, and combinations of these with, for example, 1-dodecylazacycloheptan-2-one sold under the trademark Azone by Nelson Research and Development; decyl methyl sulfoxide, dimethyl sulfoxide,

salicylic acid derivatives, N,N-diethyl-m-tolamide, crotamiton, 1-substituted azacycloalkan-2-ones such as disclosed in U.S. Patent 4,316,893 for example compounds of the formula:



wherein R is H or a lower alkyl group, m is 5-7 and n is 0-17, preferably 1-11, and various other compounds which are biologically compatible and have transdermal permeation activity. Ethyl alcohol is ineffective or substantially ineffective for enhancing absorption in compositions according to the invention and therefore ethyl alcohol and other short chain alkanols (with 1-4 carbon atoms) which have substantially the same properties and activity as ethyl alcohol do not come within the term "skin absorbing enhancer" as used herein.

The invention further provides a method of producing a transdermal pharmaceutical-containing polymer matrix dosage unit having an Enhancing Factor as herein defined of at least 1.2, which method comprises:

(a) adhering one side of a polymer matrix disc layer which has microdispersed therein an amount of the pharmaceutical which will provide a dosage amount of the pharmaceutical to be delivered transdermally to a backing layer which is substantially impervious to said pharmaceutical, and


(b) adhering the other side of said polymer matrix disc layer

to an adhesive layer which has distributed therein an effective amount of one or more skin absorption enhancers which provide substantial skin absorption enhancement for said pharmaceutical.

The following examples illustrate the invention and are not intended to be limiting.

EXAMPLE 1

A dispersion of 10 parts by weight each of pure nitroglycerin oil and lactose is made using a high-torque mixer (sold by Cole-Parmer Company). The nitroglycerin-lactose dispersion is homogeneously dispersed in 70 parts of silicone elastomer using the high-torque mixer and about 1,000 RPM. The silicone elastomer is a polydimethylsiloxane polymer sold by Dow-Corning Company under the designation Silastic Medical Grade 382 Elastomer. The elastomer is believed to have the following structural formula:



wherein n indicates the number of repeating units.

With continued agitation, 10 parts of DC-360 (silicone medical fluid) and 30 drops (for every 100 g of the mixture) of a cross-linking agent designated as catalyst M is added, which is stannous octanoate. After each addition, of the mixture, material is thoroughly mixed, and the dispersed mixture is placed under vacuum to remove entrapped air.

The nitroglycerin-polydimethylsiloxane dispersion is placed into a device maker and is cross-linked at an elevated temperature (25°-60°C) to form a cross-linked, medicated polymer sheet, which has a thickness of 0.2-2 mm.

The medicated polymer sheet is removed from the device maker and is cut into circular discs of about 3-20 sq.cm. The discs are attached to a backing layer of heat sealable polyester film which is laminated to aluminum foil.

This laminate is sold by 3M Company as Scotchpak 1005. The medicated discs are attached using an adhesive polymer solution, which is a silicone adhesive polymer sold by Dow Corning as DC-355. Alternately, the discs can be formed directly on the backing layer and in practice are.

The skin permeation enhancer-adhesive layer is made by dissolving 6.5 parts by weight of a skin permeation enhancer in 30 parts of acetone. The acetone solution then is added to 100 parts of a silicone adhesive solution sold by Dow-Corning under the designation of DC-355.

The mixture is thoroughly mixed to form a homogeneous mixture of skin permeation enhancer and adhesive polymer, which is applied to a strip of a release liner which is a siliconized polyester film to permit easy removal of the film just prior to application of the final polymer matrix disc

dosage unit to the subject to be transdermally treated. The adhesive mixture is applied at a controlled thickness. The formed layer has a thickness of about 50-200 microns. The layer is dried completely in vacuum to remove volatile matter.

The skin permeation enhancer-adhesive polymer layer with releas liner is applied onto the pharmaceutical-containing polymer matrix disc with the attached backing layer under a constant pressure to provide a firmly adhered strip of a four-layered structure as follows:

1. Backing layer
2. Pharmaceutical-containing polymer matrix layer.
3. Skin permeation enhancer-adhesive layer
4. Release film layer which can be readily removed to permit application to the skin of the subject to receive transdermally the nitroglycerin.

By use of an appropriate cutter, the strip is cut to provide the transdermal nitroglycerin polymer matrix dosage units which are circular in shape and have an area of about 20 sq. cm.

The above polymer matrix disc dosage units are made using the following skin permeation enhancers: oleic acid; propyl oleate; decyl methyl sulfoxide; and 1-dodecylazacycloheptan-2-one.

Use of tert-butyl alcohol did not function as a skin permeation enhancer but rather the dosage units using tert-butyl alcohol resulted in less nitroglycerin absorption than the absorption from a controlled unit in which no enhancer compound was added to the adhesive layer.

The transdermal absorption of the pharmaceutical from the pharmaceutical polymer matrix dosage units of this invention is evaluated by use of skin from a "hairless" mouse or human cadaver by following the procedure described by P.R. Keshary and Y.W. Chien, in Drug Develop. & Ind. Pharm., 10 (6) 883-913 (1984).

Table I shows the transdermal absorption of nitroglycerin from the nitroglycerin-containing polymer matrix disc dosage units made by the above procedure. Table II shows the effect of the skin permeation enhancer concentration in the adhesive layer on the enhancement of transdermal absorption of nitroglycerin and Table III shows the skin permeation enhancement of nitroglycerin by enhancers in combination.

TABLE I

TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF ANTI-ANGINAL DRUG - NITROGLYCERIN

<u>Enhancers⁽¹⁾</u>	<u>Normalized Permeation Rate</u>	<u>Enhancing Factors⁽²⁾</u>
(1.6 MG/CM ²)	(MCG/CM ² /HR ± S.D.)	
None	25.72 ± 5.41	1.00
Stearic Acid	27.26 ± 2.53	1.06
Stearyl Alcohol	25.38 ± 0.05	0.99
Stearyl Propyl Ester	42.91 ± 4.81	1.67
Mono-Stearin	36.82 ± 0.01	1.43
Oleic Acid	70.55 ± 11.06	2.74
Oleyl Alcohol	61.74 ± 5.83	2.40
Oleyl Propyl Ester	62.40 ± 11.12	2.43 Mono-Olein 51.14
± 10.52	1.99	
Myristic Acid	28.04 ± 1.33	1.09
Myristyl Alcohol	45.72 ± 2.33	1.78
Myristyl Propyl Ester	49.46 ± 5.62	1.92
Mono-Myristein	22.54 ± 2.90	0.88
1-Dodecylazacycloheptan-		
2-One	35.83 ± 3.90	1.39
Decyl Methyl Sulfoxide	56.68 ± 1.82	2.20
Tert-Butanol	22.73 ± 2.02	0.88

1) Contained in the Adhesive Layer at a Surface Concentration of
1.6 MG/CM²

2) Enhancing Factor = $\frac{(\text{Normalized Permeation Rate}) \text{ Enhancer}}{25.72}$

TABLE II

50 EFFECT OF SKIN PERMEATION ENHANCER CONCENTRATION IN ADHESIVE LAYER ON THE ENHANCEMENT OF TRANSDERMAL ABSORPTION OF NITRO-GLYCERIN

55

60

65

Enhancing Conc. (mg/cm ²)	Enhancing Factor				
	A*	B	C	D	E
0	1.00	1.00	1.00	1.00	1.00
0.08	1.16	--	--	--	--
0.20	1.41	--	--	--	--
0.37	1.68	--	--	--	--
0.66	2.41	--	--	--	--
0.80	--	1.67	1.22	1.56	1.35
0.96	1.99	--	--	--	--
1.27	1.41	--	--	--	--
1.59	1.44	1.92	2.43	2.58	2.02
3.18	1.51	3.07	3.08	1.50	1.66
4.78	--	3.41	3.78	1.74	1.54

*Enhancer A = 1-Dodecylazacycloheptan-2-one

B = propyl myristate

C = propyl olcate

D = 1-monolauroyl-rac-glycerol

E = Myristic acid, N,N-dimethylamide

40

SKIN PERMEATION ENHANCEMENT OF NITROGLYCERIN BY ENHANCERS IN COMBINATION

TABLE III

Skin Permeation Enhancers (mg/cm ²)			Enhancing Factor
A*	B	C	
1.27	--	--	1.41
1.27	1.27	--	1.63
1.27	--	1.27	2.15
--	1.27	1.27	1.28
1.27	1.27	1.27	2.37

*Enhancer A = 1-Dodecylazacycloheptan-2-one

B = propyl myristate

C = propyl oleate

65

EXAMPLE 2

The following dosage units are made and evaluated, using the general procedure set out in Example 1. No dispersing agent is employed in fabricating the polymer matrix discs.

TABLE IV

TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF ANTI-ARRHYTHMIC DRUG -VERAPAMIL

<u>Enhancers</u> (3.2 MG/CM ²)	<u>Normalized Permeation Rate</u> (MCG/CM ² /HR \pm S.D.)	<u>Enhancing Factors</u>
None	4.58 \pm 1.55	1.00
Propyl Myristate	9.03 \pm 2.40	1.97
Propyl Oleate	11.70 \pm 2.25	2.73
1-Dodecylazacycloheptan-2-One	11.55 \pm 2.04	2.52

EXAMPLE 3

The following dosage units are made following the general procedure of Example 1. The following ingredients are used in making the pharmaceutical-containing polymer matrix discs: pharmaceutical, 10 parts; DC-360 polysiloxane medical fluid (20 cps), 10 parts; silicone (medical-grade) elastomer, 80 parts, and catalyst M (20 drops/100g. of mixture).

The pharmaceutical crystals (10 parts) are dispersed in 10 parts of DC-360 silicone medical fluid to a uniform dispersion. The pharmaceutical dispersion is homogeneously dispersed in 80 parts of Silastic medical-grade 382 elastomer.

30 The skin permeation enhancer-adhesive film is made using the following ingredients: skin permeation enhancer, 6.5 parts; solvent, 30 parts; and adhesive polymer solution, 100 parts.

Transdermal polymer matrix dosage units are obtained and evaluated as shown in Tables V-XI.

35 TABLE V

40 TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF PROGESTATIONAL STEROID -PROGESTERONE

<u>Enhancers</u> (3.2 MG/CM ²)	<u>Normalized Permeation Rate</u> (MCG/CM ² /HR \pm S.D.)	<u>Enhancing Factors</u>
None	1.53 \pm 0.43	1.00
Propyl Myristate	6.98 \pm 1.33	4.56
Propyl Oleate	8.20 \pm 1.72	5.36
1-Dodecylazacycloheptan-2-One	9.12 \pm 3.53	5.96

TABLE VI

65 TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF ANTI-INFLAMMATORY STEROID -HYDROCORTISONE

<u>Enhancers</u> (3.2 MG/CM ²)	<u>Normalized Permeation Rate</u> (MCG/CM ² /HR ± S.D.)	<u>Enhancing Factors</u>
None	0.046 ± 0.005	1.00
Propyl Myristate	0.21 ± 0.073	4.57
Propyl Oleate	0.23 ± 0.045	5.00
1-Dodecylazacycloheptan-2-One	2.82 ± 0.58	61.30

20

TABLE VII

TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF ANALGESIC DRUG - HYDROMORPHONE

<u>Enhancers</u> (3.2 MG/CM ²)	<u>Normalized Permeation Rate</u> (MCG/CM ² /HR ± S.D.)	<u>Enhancing Factors</u>
None	0.103 ± 0.022	1.00
Propyl Myristate	0.41 ± 0.11	3.98
Propyl Oleate	0.37 ± 0.098	3.59
1-Dodecylazacycloheptan-2-One	0.94 ± 0.35	9.13

45

TABLE VIII

TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF ANTI-ARTHRITIC DRUG -INDOMETHACIN

<u>Enhancers</u> (3.2 MG/CM ²)	<u>Normalized Permeation Rate</u> (MCG/CM ² /HR ± S.D.)	<u>Enhancing Factors</u>
None	0.39 ± 0.08	1.00
Propyl Myristate	1.47 ± 0.10	3.77
Propyl Oleate	1.82 ± 0.39	4.67
1-Dodecylazacycloheptan-2-One	5.65 ± 0.89	14.49

TABLE IX

TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF ANTI-ARTHRITIC DRUG -INDOMETHACIN BY USING COMBINATION OF ENHANCERS

5

Enhancers* (3.2 MG/CM ²)	Normalized Permeation Rate (MCG/CM ² /HR \pm S.D.)	Enhancing Factors ^{Δ}
None	0.32 \pm 0.08	1.00
Oleic Acid	4.31 \pm 0.85	13.47
Oleyl Alcohol	4.88 \pm 0.61	15.25
Oleyl Acetate	6.07 \pm 0.65	18.96
Propyl Oleate	2.70 \pm 0.002	8.44
Monoolein	2.30 \pm 0.42	7.19
Propyl Myristate	2.87 \pm 0.55	8.98
Myristyl Alcohol	1.63 \pm 0.32	5.10
Myristyl		
N,N-Dimethyl Amide	3.85 \pm 0.07	12.02

*The adhesive layer contains equal concentrations of 1-dodecylazacycloheptan-2-one and second named enhancer. ^{Δ} The enhancing factor for 1-dodecylazacycloheptan-2-one alone (1.6 MG/CM²) is 7.48.

TABLE X

50

TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF ANDROGENIC STEROID -TESTOSTERONE

55

60

65

<u>Enhancers</u>	<u>Conc.</u> (mg/cm ²)	<u>Normalized</u> <u>Permeation Rate</u> (mcg/cm ² /hr ±SD)	<u>Enhancing Factor</u>
None	0.00	0.57 ± 0.04	1.00
N,N-Diethyl-m toluamide	1.60 3.20	1.06 ± 0.06 2.61 ± 0.11	1.86 4.58
1-Dodecylazacycloheptan- 2-one	1.60	4.29 ± 2.28	7.53
1-Dodecylazacycloheptan- 2-one+	1.60		
Oleyl alcohol	1.60	4.37 ± 0.72	7.67
1-Dodecylazacycloheptan- 2-one+	1.60		
Myristyl-N,N-dimethylamide	1.60	7.62 ± 0.92	13.37
1-Dodecylazacycloheptan- 2-one+	1.60		
Decylmethylsulfoxide	1.60	8.92 ± 0.96	15.65

TABLE XI

TRANSDERMAL ABSORPTION FROM POLYMER MA-
TRIX DISC DOSAGE UNITS CONTAINING DECYL
METHYL SULFOXIDE AS SKIN ABSORPTION ENHAN-
CER

35

40

45

50

55

60

65

<u>Drugs</u>	<u>Enhancer Conc.</u> (MG/CM ²)	<u>Permeation Rate</u> (MCG/CM ² /HR \pm S.D.)	<u>Enhancing Factors</u>
Nitroglycerin	0	34.48 \pm 7.03	1.00
	5	46.74 \pm 1.74	1.36
	10	41.91 \pm 0.06	1.22
Indomethacin	0	0.49 \pm 0.22	1.00
	5	2.68 \pm 0.30	5.47
	10	7.68 \pm 0.31	15.67
Progesterone	0	1.11 \pm 0.68	1.00
	5	8.02 \pm 0.14	7.23
	10	12.25 \pm 0.61	11.04
Hydrocortisone	0	0.065 \pm 0.001	1.00
	5	0.72 \pm 0.094	11.08
	10	1.64	25.23
Verapamil	0	3.45 \pm 0.55	1.00
	5	8.14 \pm 1.06	2.36
	10	11.73 \pm 3.07	3.40
Hydromorphone	0	0.103 \pm 0.022	1.00
	5	0.43 \pm 0.008	4.17
	10	0.95 \pm 0.22	9.22

EXAMPLE 4

The following dosage units are made following the general procedure of Example 1. The following ingredients are used in making the pharmaceutical-containing polymer matrix discs: estradiol, 5 parts; aqueous solution of polyethylene glycol-mol. wt.400 (40% v/v), 20 parts DC-360 polysiloxane medical fluid (20 cps), 5 parts; silicone (medical-grade) elastomer, 70 parts; catalyst M, 20 drops per 100g. of the mixture.

The estradiol crystals are thoroughly dispersed in the polyethylene glycol solution, which is homogeneously dispersed in the 70 parts of Silastic medical-grade 382 elastomer.

35 The skin permeation enhancer-adhesive film is made using the following ingredients: skin permeation enhancer, 6.5 parts; solvent 30 parts; and adhesive polymer solution, 100 parts. Transdermal polymer matrix dosage units are obtained and evaluated as shown in Table XII.

40 TABLE XII

45 TRANSDERMAL ABSORPTION FROM POLYMER MATRIX DISC DOSAGE UNITS OF ESTROGENIC STEROID-ESTRADIOL

50

55

60

65

Enhancers (3.2 MG/CM ²)	Normalized Permeation Rate (MCG/CM ² /HR ± S.D.)	Enhancing Factors
None	1.22 ± 1.06	1.00
Propyl Myristate	11.38 ± 3.38	9.33
Propyl Oleate	17.84 ± 8.20	14.62
1-Dodecylazacycloheptan- 2-One	24.61 ± 8.93	20.17
Decyl Methyl Sulfoxide	15.36 ± 0.45	12.59

Claims

1. A transdermal pharmaceutical-containing polymer matrix dosage unit comprising:

a) a backing layer which is substantially impervious to the pharmaceutical to be delivered transdermally;

b) a polymer matrix disc layer which is adhered to said backing layer and which has microdispersed therein an amount of the pharmaceutical which will provide a dosage amount of the pharmaceutical to be delivered transdermally; and

25 c) an adhesive layer which is adhered to said pharmaceutical-containing polymer matrix disc layer and which has distributed therein an effective amount of one or more skin absorption enhancers which provide substantial skin absorption enhancement for said pharmaceutical;


30

said dosage unit having an Enhancing Factor as herein defined of at least 1.2.

35

2. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in claim 1 wherein the polymer matrix disc layer is a cross-linked polysiloxane polymer of the following formula:

40



65


wherein R is alkyl or alkoxy having 1-7 carbon atoms, vinyl, phenyl or a combination thereof and wherein n is about 100 to about 5,000.

3. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in claim 2 wherein R in the poly-

siloxan formula is propoxy.

4. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 3 wherein the polymer matrix disc layer has a thickness of from 0.05 to 5mm.

5. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 4 wherein the polymer matrix disc provides microdispersion compartments having a cross sectional dimension of from about 10 to about 200 microns.



wherein R is H or a lower alkyl group, m is 5-7 and n is 0-17, saturated and unsaturated fatty acids and their alkyl esters, alcohols, monoglycerides, diethanolamides, triethanolamine complexes, and N, N-dimethylamide derivatives, and acetate esters of said alcohol derivatives; propyl myristate; myristyl alcohol; propyl oleate; oleic acid; oleyl alcohol; oleyl acetate; monoolein; myristyl N, N-dimethyl amide; stearic acid; stearyl alcohol; propyl stearate; mono-stearin; mono-myristein; salicylic acid and derivatives; glycylglycine; N,N-diethyl-m-toluamide; crotonamiton; and combinations thereof.

9. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 8 wherein the adhesive layer has distributed therein from about 1 to about 30 per cent of one or more skin absorption enhancers based on the weight of the polysiloxane adhesive.

10. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 9 wherein the Enhancing Factor as herein defined is at least about 2.0.

11. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 10 which has a releasable protective layer adhered to the adhesive layer.

12. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 11 wherein the pharmaceutical has anti-anginal, anti-arrhythmic, anti-hypertensive, tranquilizing, diuretic, central nervous system, anti-inflammatory, analgesic or anti-arthritis activity.

13. A transdermal pharmaceutical-containing polymer

6. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 5 wherein the adhesive layer is made from a pressure-sensitive adhesive.

7. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 6 wherein the adhesive layer is made from a silicone polymer adhesive.

8. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 7 wherein the skin absorption enhancer is selected from decyl methyl sulphoxide; 1-dodecylazacycloheptan-2-one; a compound of formula:

matrix dosage unit as claimed in any of claims 1 to 12 wherein the pharmaceutical is a steroid.

14. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in claim 13, wherein the pharmaceutical comprises testosterone, estradiol, progesterone, hydrocortisone or indomethacin.

15. A transdermal pharmaceutical-containing polymer matrix dosage unit as claimed in any of claims 1 to 12 wherein the pharmaceutical is nitroglycerin.

16. A method of producing a transdermal pharmaceutical-containing polymer matrix dosage unit having an Enhancing Factor as herein defined of at least 1.2, which method comprises:

(a) adhering one side of a polymer matrix disc-layer which has microdispersed therein an amount of the pharmaceutical which will provide a dosage amount of the pharmaceutical to be delivered transdermally to a backing layer which is substantially impervious to said pharmaceutical, and

(b) adhering the other side of said polymer matrix disc layer to an adhesive layer which has distributed therein an effective amount of one or more skin absorption enhancers which provide substantial skin absorption enhancement for said pharmaceutical.